Cascade Family Screening (ACM)
Definition
Cascade family screening refers to the systematic cardiovascular and genetic evaluation of first-degree relatives of a proband with a confirmed ACM diagnosis. It is ideally conducted within a multidisciplinary cardiovascular genetics program and aims to identify disease early, enable lifestyle modification, and inform ICD decisions before a sentinel arrhythmic event.
Key Concepts
Rationale
- ACM is predominantly inherited as an autosomal dominant trait → first-degree relatives have a 50% a priori risk of harboring the familial variant.
- Penetrance is incomplete and age-related; disease expression is less severe in relatives than probands and occurs at an older age.
- Arrhythmic events in family members appear to occur only in the presence of manifest ECG and structural changes — making early detection actionable. (sources/acm-hrs-2019)
Screening Recommendations
- COR I, LOE C-EO: A genetic counselor or appropriately experienced clinician should obtain a comprehensive 3-generation family history from the proband.
- COR I, LOE B-NR: First-degree relatives should undergo clinical evaluation every 1–3 years starting at age 10–12 years.
- COR I, LOE B-NR: Cardiovascular evaluation includes: 12-lead ECG, ambulatory ECG monitoring, and cardiac imaging (echo, CMR, or CT depending on availability).
- COR IIb, LOE C-LD: Exercise stress testing may be considered as an adjunct to expose latent phenotype by initiating ventricular ectopy. (sources/acm-hrs-2019)
Genetic Cascade Testing
- Offered to first-degree relatives only when a class 4 (likely pathogenic) or class 5 (pathogenic) variant has been identified in the proband.
- Cascade testing requires comprehensive pretest genetic counseling (process, implications, psychosocial impact, insurance issues).
- Family members negative for a class 5 variant may be released from regular cardiological follow-up (COR IIb, LOE C-EO) but should be educated to return if symptoms develop.
- Family members negative for a class 4 variant remain in follow-up at longer intervals (individualized by clinical team).
- Class 3 (VUS) variants should not drive cascade testing unless reclassified. (sources/acm-hrs-2019)
Pediatric Considerations
- Disease expression under age 10 is almost exclusively seen in probands; relatives rarely develop disease this early.
- Cascade testing in minors is controversial; testing is typically deferred until clinical features become likely, guided by the child's best interest, and conducted by a multidisciplinary team including cardiologists, geneticists, genetic counselors, and psychologists.
Expected Diagnostic Yield
- In PKP2 families: approximately one-third of relatives have a diagnosis of ARVC, one-third have borderline disease, and one-third are unaffected.
- Overall, relatives have less severe disease, are more commonly asymptomatic, and have later onset than probands.
- Among at-risk relatives, electrocardiographic changes typically occur earlier and more commonly than structural changes; however, LGE on CMR (most frequently in LV) can be the first evidence of disease in a small subset. (sources/acm-hrs-2019)
ESC 2023 Updates to Family Screening
- A 3–4-generation family pedigree is mandatory at initial evaluation for all patients with suspected cardiomyopathy (Class I, Level C), to identify inheritance pattern and at-risk relatives. (sources/esc-cmp-2023)
- Contrast-enhanced CMR should be considered in genotype-positive/phenotype-negative family members to aid early diagnosis (Class IIa, Level B). (sources/esc-cmp-2023)
- Relatives who do not carry the confirmed familial P/LP variant can generally be discharged from clinical follow-up. (sources/esc-cmp-2023)
- Cascade testing is NOT indicated when a variant of uncertain significance (VUS) is identified in the proband — only for confirmed P/LP variants. (sources/esc-cmp-2023)
- Transition of care from paediatric to adult cardiomyopathy services requires timely preparation and joint consultations (Class I, Level C). (sources/esc-cmp-2023)
- Psychological support is recommended for all individuals who have experienced the premature SCD of a family member with cardiomyopathy (Class I, Level B). (sources/esc-cmp-2023)
HFSA 2018 — Cardiomyopathy Phenotypic Screening Intervals
- Baseline phenotype screening recommended for all at-risk 1st-degree relatives regardless of genetic status (Level A); relatives confirmed genotype-negative for a known P/LP variant may be discharged from serial surveillance after baseline evaluation (sources/genetic-cmp-jcf-2018 — very high)
- Serial screening recommended for relatives with unknown genetic status or confirmed P/LP carriers (sources/genetic-cmp-jcf-2018 — very high)
- Suggested screening intervals by age and cardiomyopathy type:
| Cardiomyopathy | 0–5 yr | 6–12 yr | 13–19 yr | 20–50 yr | >50 yr |
|---|---|---|---|---|---|
| DCM | Annually (+ FDR) | Every 1–2 yr | Every 1–3 yr | Every 2–3 yr | Every 5 yr |
| HCM | Annually (+ FDR) | Every 1–2 yr | Every 2–3 yr | Every 5 yr | Every 5 yr |
| ARVC | Once (consider, + FDR) | Every 5 yr | Every 1–3 yr | Every 2–3 yr | Every 3 yr |
| RCM | Annually (+ FDR) | Every 1–2 yr | Every 2–3 yr | Every 3 yr | Every 5 yr |
- Studies at each screening visit: ECG (all), 2D echo (all), Holter (HCM, ARVC), cardiac MRI when echo insufficient, CK-MM if neuromuscular disease suspected, metabolic screening for paediatric-onset (sources/genetic-cmp-jcf-2018 — very high)
HCM-Specific Family Screening (AHA 2024)
- 3-generation family history mandatory at initial HCM assessment (Class I). (sources/HCM-AHA-2024)
- Screening intervals (ECG + echo) for first-degree relatives:
- Children in genotype-positive families or families with early-onset disease: start when HCM diagnosed in family member; repeat every 1–2 years.
- All other children/adolescents: start no later than puberty; repeat every 2–3 years.
- Adults: start at time of HCM diagnosis in family member; repeat every 3–5 years. (sources/HCM-AHA-2024)
- Cascade genetic testing: Offered when a pathogenic or likely pathogenic (P/LP) variant identified in the proband; genotype-negative relatives can be released from ongoing clinical surveillance. (sources/HCM-AHA-2024)
- Serial variant reclassification (Class I, Level B-NR): P/LP classification can change — 11% of HCM variants reclassified over 6 years in one study. Re-evaluate pathogenicity every 2–3 years; notify relatives if variant is downgraded and recommence clinical screening. (sources/HCM-AHA-2024)
- Postmortem genetic testing (Class I): When sudden unexplained death with HCM at autopsy — facilitates cascade testing in living relatives. (sources/HCM-AHA-2024)
- If proband has no identified P/LP variant: cascade genetic testing is NOT useful (Class III: No Benefit); ongoing clinical screening of relatives still required. (sources/HCM-AHA-2024)
- VUS in proband: clinical genetic testing of phenotype-negative relatives for reclassification purposes has uncertain usefulness (Class IIb); should only be done with cardiovascular genetics expert guidance. (sources/HCM-AHA-2024)
- Genotype-positive, phenotype-negative individuals: Serial ECG + cardiac imaging every 1–2 years (children) or 3–5 years (adults); screening generally continued until ~50 years of age. (sources/HCM-AHA-2024)
Real-World Cascade Testing Yield — Combined Cardiomyopathy + Arrhythmia Panel (JAMA Cardiology 2022)
- In 954 index patients with a positive combined panel result (n=4,782 total cohort), 306 (32.1%) had family members referred for cascade testing (sources/genetic-yield-jama-card-2022 — high)
- 958 family members received cascade testing (mean 3.1 per index patient, range 1–17)
- 42.0% of family members received a positive result — confirming substantial familial genetic burden
- 46.5% received a negative result — freed from intensive longitudinal surveillance; this "clearance" benefit is one of the primary values of cascade genetic testing
- Use of a combined panel (vs. disease-specific panel) for the index patient also benefited cascade testing: approximately 1 in 23 family members with positive results would have been missed if restricted panels had been used for the index patient
- Cascade testing was utilised more frequently in postmortem-positive cases (61.1%) than in living-positive cases (32.1%) — highlighting the value of molecular autopsy for family protection
- 40.9% of family members of postmortem-positive decedents tested positive — demonstrating the yield of cascade testing even after a sudden death index case
Cascade Screening for Inherited Arrhythmias (EHRA/HRS/APHRS/LAHRS)
- Genetic testing of first-degree relatives is indicated once a class 4/5 variant is identified in the proband — applicable to LQTS, BrS, CPVT, SQTS, and other arrhythmia syndromes with positive family history. (sources/arrhythmia-genetics-mgenetik-2025)
- Variant reclassification rates >36% in channelopathies mean that results communicated to family members can change over time — requiring periodic re-evaluation and active notification protocols. (sources/arrhythmia-genetics-mgenetik-2025)
- Best executed in interdisciplinary cardiogenetic centres combining electrophysiology, imaging, genetics, and genetic counselling. Access is currently limited to academic centres. (sources/arrhythmia-genetics-mgenetik-2025)
- Diagnostic scores for inherited arrhythmias (Schwartz score for LQTS, Shanghai score for BrS) already incorporate the presence of a pathogenic variant — making a confirmed genetic result clinically equivalent to full diagnosis in some syndromes. (sources/arrhythmia-genetics-mgenetik-2025)
Incidental Variant Cascade Testing (AHA 2023)
- LP/P incidental variants — once confirmed as disease-associated by the Bayesian framework — should trigger cascade genetic testing in first-degree relatives, regardless of whether the proband is phenotypically affected (sources/incident-gene-aha-2023 — high)
- Cascade testing must NOT be performed on VUS variants from incidental contexts, identical to the rule for diagnostic probands (sources/incident-gene-aha-2023 — high)
- Genotype-positive family members found via incidental variant cascade testing should undergo the same three-step Bayesian evaluation framework (pretest probability → variant pathogenicity re-evaluation → posttest probability)
- Genotype-positive relatives without phenotypic evidence of disease still require longitudinal follow-up at guideline-directed intervals
- The Bayesian framework should be conducted at or in close consultation with a specialised multidisciplinary cardiovascular genetics centre (sources/incident-gene-aha-2023 — high)
- See concepts/Incidental-Cardiovascular-Variants for the complete Bayesian evaluation framework
DTC-GT Cascade Testing — Challenges and Gaps
- Traditional cascade testing adoption in clinical genetics workflows is <50%; the specific frequency for DTC-GT-triggered cascade testing is unknown (sources/consumer-genetictest-aha-2025 — high)
- DTC companies do NOT actively facilitate cascade testing — unlike clinical genetics services that provide family letters and contact protocols; patients must self-initiate family communication (sources/consumer-genetictest-aha-2025 — high)
- No current professional guidelines address cascade screening specifically after DTC-GT results — this is a major regulatory and clinical gap given that >33 million DTC-GTs were performed in 2022 (sources/consumer-genetictest-aha-2025 — high)
- DTC-GT cascade testing risks: misclassified variants (especially from SNP-chip based tests) may generate false-positive results that, if shared with family members, lead to unnecessary stress, procedures, and financial burdens (sources/consumer-genetictest-aha-2025 — high)
- PRS cascade testing is not strongly indicated given the non-mendelian nature of polygenic risk; however, high concordance between first-degree relatives with high CAD PRS (Reid et al., Circ Genom Precis Med 2021) may justify consideration (sources/consumer-genetictest-aha-2025 — high)
- Confirmatory CLIA-certified testing should precede any DTC-GT-triggered cascade testing — to avoid propagating potentially erroneous results through families (sources/consumer-genetictest-aha-2025 — high)
- See concepts/DTC-Genetic-Testing for full clinical approach framework
AHA 2020 — Legal and Institutional Context for Cascade Testing
- HIPAA (US) restricts providers from directly contacting at-risk relatives without patient authorization; providers should supply patients with a standardized family letter accurately summarizing the genetic finding and directing relatives toward cascade evaluation (sources/genetic-test-aha-2020 — high)
- Genetic Information Nondiscrimination Act (GINA 2008): prohibits genetic discrimination in health insurance and employment; does NOT cover life insurance, disability insurance, or long-term care insurance; does not apply to employers with <15 employees — patients must be counselled about these limitations before undergoing testing (sources/genetic-test-aha-2020 — high)
- When cascade extends beyond the immediate family: for any family member found to have the disease phenotype or a positive genetic result, their own first-degree relatives should in turn be offered testing — the cascade continues outward until all at-risk relatives have been offered clinical screening and genetic testing (sources/genetic-test-aha-2020 — high)
- Family members who test negative for the familial P/LP variant: exonerated from further structured surveillance (risk reverts to general population level); exception if clinical phenotype is atypical for the identified variant, oligogenic contribution is suspected, or penetrance uncertainty remains (sources/genetic-test-aha-2020 — high)
- Family members who decline genetic testing: uncertain genetic status — clinical surveillance recommended at the same intervals as genotype-positive individuals (sources/genetic-test-aha-2020 — high)
- Prenatal genetic testing and preimplantation genetic diagnosis (PGD): a confirmed familial P/LP variant enables prospective parents to consider these reproductive management options (sources/genetic-test-aha-2020 — high)
Contradictions / Open Questions
- VUS variant handling — testing vs. not testing relatives: Both HRS 2019 and ESC/AHA guidelines agree that VUS variants should not drive cascade genetic testing of relatives. However, in practice, a significant proportion of HCM and ACM probands carry VUS rather than confirmed P/LP variants — meaning the majority of families with a likely inherited disease still cannot access gene-informed cascade testing. The gap between the recommendation (don't test for VUS) and clinical reality (most probands have VUS) is substantial. (sources/acm-hrs-2019, sources/HCM-AHA-2024)
- Serial reclassification responsibility: AHA 2024 recommends re-evaluating variant pathogenicity every 2–3 years (Class I, Level B-NR). In practice, there is no standardized system for notifying relatives when a variant is downgraded from P/LP to VUS (or upgraded). If a relative was told they are "gene-negative" based on a proband variant later upgraded to P/LP, they may have been incorrectly discharged from follow-up. The clinical infrastructure for systematic reclassification notification does not yet exist in most centers. (sources/HCM-AHA-2024)
- Screening interval heterogeneity across guidelines: ACM screening (HRS 2019): every 1–3 years from age 10–12. HCM screening (AHA 2024): every 1–2 years for children, every 3–5 years for adults. The difference reflects disease-specific penetrance rates but can create confusion for individuals with mixed or uncertain phenotypes. (sources/acm-hrs-2019, sources/HCM-AHA-2024)
Connections
- Related to concepts/Arrhythmogenic-Cardiomyopathy
- Related to entities/ARVC
- Related to entities/ALVC
- Related to entities/PKP2
- Related to entities/HCM
- Related to concepts/Cardiogenetic-Centers
- Related to concepts/Variant-Reclassification
- Related to entities/Long-QT-Syndrome
- Related to entities/Brugada-Syndrome
- Related to entities/CPVT
- Related to concepts/Genetic-Testing-in-Cardiomyopathy
- Related to sources/genetic-cmp-jcf-2018
- Related to concepts/DTC-Genetic-Testing
- Related to concepts/Incidental-Cardiovascular-Variants
- Related to sources/incident-gene-aha-2023
- Related to sources/genetic-test-aha-2020